Logo image of CVAC

CUREVAC NV (CVAC) Stock Price, Quote, News and Overview

NASDAQ:CVAC - Nasdaq - NL0015436031 - Common Stock - Currency: USD

3.12  -0.08 (-2.5%)

After market: 3.12 0 (0%)

CVAC Quote, Performance and Key Statistics

CUREVAC NV

NASDAQ:CVAC (4/17/2025, 8:11:20 PM)

After market: 3.12 0 (0%)

3.12

-0.08 (-2.5%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High5.28
52 Week Low2.22
Market Cap699.94M
Shares224.34M
Float122.80M
Yearly DividendN/A
Dividend YieldN/A
PE3.8
Fwd PEN/A
Earnings (Next)05-21 2025-05-21
IPO08-14 2020-08-14


CVAC short term performance overview.The bars show the price performance of CVAC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

CVAC long term performance overview.The bars show the price performance of CVAC in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60 -80

The current stock price of CVAC is 3.12 USD. In the past month the price increased by 5.05%. In the past year, price increased by 27.87%.

CUREVAC NV / CVAC Daily stock chart

CVAC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.23B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.88B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About CVAC

Company Profile

CVAC logo image CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 999 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

Company Info

CUREVAC NV

Friedrich-Miescher-Str. 15

Tuebingen BADEN-WUERTTEMBERG 72076 DE

CEO: Franz-Werner Haas

Employees: 1086

Company Website: https://www.curevac.com/

Investor Relations: https://www.curevac.com/en/investor-relations/

Phone: 49707198830

CUREVAC NV / CVAC FAQ

What is the stock price of CUREVAC NV today?

The current stock price of CVAC is 3.12 USD. The price decreased by -2.5% in the last trading session.


What is the ticker symbol for CUREVAC NV stock?

The exchange symbol of CUREVAC NV is CVAC and it is listed on the Nasdaq exchange.


On which exchange is CVAC stock listed?

CVAC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CUREVAC NV stock?

13 analysts have analysed CVAC and the average price target is 7.87 USD. This implies a price increase of 152.2% is expected in the next year compared to the current price of 3.12. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CUREVAC NV worth?

CUREVAC NV (CVAC) has a market capitalization of 699.94M USD. This makes CVAC a Small Cap stock.


How many employees does CUREVAC NV have?

CUREVAC NV (CVAC) currently has 1086 employees.


What are the support and resistance levels for CUREVAC NV (CVAC) stock?

CUREVAC NV (CVAC) has a resistance level at 3.2. Check the full technical report for a detailed analysis of CVAC support and resistance levels.


Is CUREVAC NV (CVAC) expected to grow?

The Revenue of CUREVAC NV (CVAC) is expected to decline by -85.66% in the next year. Check the estimates tab for more information on the CVAC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CUREVAC NV (CVAC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CUREVAC NV (CVAC) stock pay dividends?

CVAC does not pay a dividend.


When does CUREVAC NV (CVAC) report earnings?

CUREVAC NV (CVAC) will report earnings on 2025-05-21.


What is the Price/Earnings (PE) ratio of CUREVAC NV (CVAC)?

The PE ratio for CUREVAC NV (CVAC) is 3.8. This is based on the reported non-GAAP earnings per share of 0.82 and the current share price of 3.12 USD. Check the full fundamental report for a full analysis of the valuation metrics for CVAC.


What is the Short Interest ratio of CUREVAC NV (CVAC) stock?

The outstanding short interest for CUREVAC NV (CVAC) is 3.19% of its float. Check the ownership tab for more information on the CVAC short interest.


CVAC Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CVAC. When comparing the yearly performance of all stocks, CVAC is one of the better performing stocks in the market, outperforming 74.42% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CVAC Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to CVAC. CVAC has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CVAC Financial Highlights

Over the last trailing twelve months CVAC reported a non-GAAP Earnings per Share(EPS) of 0.82. The EPS increased by 161.38% compared to the year before.


Industry RankSector Rank
PM (TTM) 30.3%
ROA 20.2%
ROE 23.28%
Debt/Equity 0.05
Chartmill High Growth Momentum
EPS Q2Q%63.15%
Sales Q2Q%-35.88%
EPS 1Y (TTM)161.38%
Revenue 1Y (TTM)895.5%

CVAC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to CVAC. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -167.63% and a revenue growth -85.66% for CVAC


Ownership
Inst Owners18.11%
Ins Owners0.18%
Short Float %3.19%
Short Ratio4.51
Analysts
Analysts78.46
Price Target7.87 (152.24%)
EPS Next Y-167.63%
Revenue Next Year-85.66%